• 1. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 2. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 3. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 4. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 5. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119

4-Oxo-2-(2-oxo-2-phenylethyl)-4-phenylbutanoic Acid: A Comprehensive Overview

4-Oxo-2-(2-oxo-2-phenylethyl)-4-phenylbutanoic acid (CAS No. 77953-17-4) is a complex organic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, often referred to by its CAS number 77953-17-4, is characterized by its unique molecular structure, which includes a ketone group, a carboxylic acid group, and phenyl substituents. These structural features contribute to its diverse biological activities and potential therapeutic applications.

The molecular formula of 4-Oxo-2-(2-oxo-2-phenylethyl)-4-phenylbutanoic acid is C₁₈H₁₆O₄, and its molecular weight is approximately 300.31 g/mol. The compound's chemical structure can be represented as follows:

In recent years, extensive research has been conducted to explore the biological properties and potential therapeutic applications of 4-Oxo-2-(2-oxo-2-phenylethyl)-4-phenylbutanoic acid. One of the key areas of interest is its anti-inflammatory activity. Studies have shown that this compound exhibits significant anti-inflammatory effects by inhibiting the production of pro-inflammatory cytokines such as TNF-alpha and IL-6. This property makes it a promising candidate for the development of new anti-inflammatory drugs.

Additionally, 4-Oxo-2-(2-oxo-2-phenylethyl)-4-phenylbutanoic acid has been investigated for its potential as an anticancer agent. Research has demonstrated that it can induce apoptosis in various cancer cell lines, including breast cancer, lung cancer, and colon cancer cells. The mechanism of action involves the modulation of signaling pathways such as the PI3K/AKT pathway and the MAPK pathway, which are crucial for cell survival and proliferation.

Beyond its anti-inflammatory and anticancer properties, 4-Oxo-2-(2-oxo-2-phenylethyl)-4-phenylbutanoic acid has also shown promise in neuroprotective studies. Preclinical studies have indicated that this compound can protect neurons from oxidative stress and neurotoxicity, making it a potential candidate for the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

The synthesis of 4-Oxo-2-(2-oxo-2-phenylethyl)-4-phenylbutanoic acid has been optimized through various methods, including classical organic synthesis routes and more modern techniques such as microwave-assisted synthesis. These advancements have improved the yield and purity of the compound, making it more accessible for further research and development.

In terms of pharmacokinetics, studies have shown that 4-Oxo-2-(2-oxo-2-phenylethyl)-4-phenylbutanoic acid has favorable absorption, distribution, metabolism, and excretion (ADME) properties. It is rapidly absorbed in the gastrointestinal tract and has a moderate half-life in vivo, which suggests its potential for oral administration in therapeutic settings.

Clinical trials are currently underway to evaluate the safety and efficacy of 4-Oxo-2-(2-oxyo-o-phehylethyl)-4-phehnylbutanoic acid in various disease conditions. Preliminary results from phase I trials have shown that the compound is well-tolerated with minimal side effects, paving the way for more advanced clinical studies.

In conclusion, 4-Oxo-oxyo-o-phehylethyl)-4-phehnylbutanoic acid (CAS No. 77953-o7-o) is a multifaceted compound with a wide range of biological activities and potential therapeutic applications. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further research and development in the fields of medicinal chemistry and pharmaceutical science.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)